Cramer: Allergan Looks Like a Growth Drug Company
Allergan reported terrific top line growth, but the stock is cheap because the entire group is out of favor, says Jim Cramer.
Allergan (AGN) - Get Report reported terrific top line growth, but the stock is cheap because the entire group is out of favor, said TheStreet's Jim Cramer. He said the stock buyback will be accretive and puts a floor under the stock.
At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.
